Advertisement Elekta to acquire CMS for $75 million - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Elekta to acquire CMS for $75 million

Elekta has signed a purchase agreement to acquire CMS for a total cash consideration of $75 million. Closing of the transaction is expected in March, 2008.

The company claims that CMS, with several leading solutions in clinical use and a strong pipeline of advanced functionality in development, will significantly contribute to Elekta’s strategy in radiation therapy planning.

Tomas Puusepp, president and CEO of Elekta, said: “The people, products and market position of CMS are highly complementary to Elekta’s corporate structure, technology portfolio and R&D roadmap. Both Elekta’s and CMS customers will benefit from our combined strength in product development and support.”